InvestorsHub Logo
Followers 1327
Posts 248681
Boards Moderated 64
Alias Born 12/07/2009

Re: None

Tuesday, 10/10/2023 1:57:16 PM

Tuesday, October 10, 2023 1:57:16 PM

Post# of 118383
"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to the company. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."


$RGBP Chief Scientific Consultant
Bullish
Bullish

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!